LivaNova (NSDQ:LIVN) said today that three separate, recently published studies highlight the performance and cost savings of its sutureless aortic valve, Perceval.
The results from the Perceval Aortic Heart Valve Study in North America found that Perceval achieves positive safety and efficacy outcomes whether or not an open or minimally invasive surgical approach is used. The multi-center, prospective, non-randomized, single-arm clinical trial included 300 patients from 18 U.S. centers and was performed under an FDA Investigational Device Exemption. The results were published in the Journal of Thoracic and Cardiovascular Surgery.
Get the full story on our sister site, Medical Design & Outsourcing.
The post LivaNova touts studies of its sutureless aortic valve appeared first on MassDevice.
from MassDevice http://bit.ly/2MhEgh1
Cap comentari:
Publica un comentari a l'entrada